

Clinigene, SCIREX to collaborate on clinical trials

07 July 2005 | News



Clinigene International, a wholly owned subsidiary of Biocon Ltd, and SCIREX Corp., a wholly owned subsidiary of the Omnicom Group, have signed a Letter of Intent (LoI) to collaborate on global clinical trials. The LoI was signed at SCIREX's headquarters in Horsham, Pennsylvania, USA, during a recent visit by Kiran Mazumdar-Shaw, chairman and managing director, Biocon and Dr Arvind Atignal, chief operating officer, Clinigene.

With India rapidly emerging as a key locale for clinical research, the new relationship provides SCIREX clients immediate access to well developed expertise in clinical investigation in India and provides Clinigene the opportunity to expand its markets and partake in global clinical trial programs. "SCIREX is extremely pleased to forge a new kind of exclusive partnership in India. We were a natural fit from the very beginning," said SCIREX CEO Jim Utterback. Shaw sees this partnership as a natural evolution for Clinigene and Biocon given the significant investment made over the past decade in systems, processes, and people. "We are proud of the leading role we have taken in India and look forward to enabling SCIREX clients to benefit from the quality and speed of clinical development in India," she said.

Kiran Mazumdar-Shaw